Form 4: Aquestive Therapeutics CFO Executes Tax Withholding
Statement of Changes in Beneficial Ownership
Aquestive Therapeutics CFO A. Ernest Toth Jr. reported the withholding of 92,652 shares to satisfy tax obligations related to vested performance stock units.
Summary
- A. Ernest Toth Jr., Chief Financial Officer of Aquestive Therapeutics, Inc., engaged in a transaction involving the withholding of 92,652 shares of common stock.
- The transaction occurred on May 5, 2026, at a price of $4.18 per share.
- The withholding was executed to satisfy tax obligations associated with the vesting of previously granted Performance Stock Units (PSUs).
- Following this transaction, the reporting person maintains beneficial ownership of 283,460 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative action regarding executive tax obligations rather than a discretionary sale of stock.
Positives
- The transaction reflects the vesting of performance-based equity, indicating the achievement of pre-defined corporate or individual performance milestones.
Negatives
- The transaction resulted in a reduction of the reporting person's direct share ownership in the company.
Risks
- None identified; this is a routine administrative transaction related to tax compliance for equity compensation.
Future Outlook
No forward-looking guidance or strategic outlook was provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that tax-related share withholding is a standard administrative procedure for executives in the biopharmaceutical sector, ensuring compliance with tax laws upon the vesting of performance-based compensation.
Comparison to Industry Standards
- The transaction is consistent with standard executive compensation practices across the biotechnology and pharmaceutical industries.
Stakeholder Impact
- Minimal impact on shareholders as the transaction is a standard tax-related equity settlement.
Key Dates
| Date | Description |
|---|---|
| 05/05/2026 | Date of the reported transaction involving the withholding of shares. |
| 05/07/2026 | Date of filing the Form 4 with the SEC. |
Keywords
Aquestive Therapeutics, AQST, Insider Trading, Form 4, CFO, Equity Compensation, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.